Sunday November 08 2009 | Biotechnology feed | All feeds
|
|
Sunday November 08 2009 | Biotechnology feed | All feeds
|
|
|
PETER LUNDBERG JOINS SOLEXA AS VP AND CHIEF TECHNICAL OFFICER Company Builds Management Team to be a Future Genomics Platform Leader CAMBRIDGE, U.K. and HAYWARD, Calif. (March 10, 2005) – Solexa, Inc. (Nasdaq: SLXA) today announced that Peter Lundberg has joined the company as vice president and chief technical officer. Mr. Lundberg will be responsible for all research and development activities at the company’s California location. Mr. Lundberg brings almost 20 years of industry experience, most recently as vice president, DNA platforms R&D at the Applied Biosystems unit of Applera Corporation. In this position, he was responsible for the development of instrument systems spanning DNA sequencing, gene expression and genotyping. His career association with Applera began in 1985 when he joined PerkinElmer, where he led the development of early preparative PCR systems, a role that enabled his move to Applied Biosystems’ PCR group. At Applied Biosystems, he served as director of engineering in the company’s PCR business unit responsible for overseeing the technical development that led to the rapid growth of real-time PCR, including its application to both gene expression and genotyping. With experience in these applications, Mr. Lundberg assumed responsibility for development of that company’s array platforms. This led to the introduction of its gene expression array platform and its multiplexed genotyping assay. Mr. Lundberg received his BS and MS degrees in Engineering Physics at Chalmers Technical University in Sweden. He holds an MBA, with a concentration in Finance, from the University of Connecticut. Commenting on his appointment, Mr. Lundberg said, “I am extremely optimistic about the potential for the Solexa’s technology and I look forward to launching the company’s new system. I believe this system’s performance can have considerable impact on the market, both in gene expression and in DNA sequencing.” Other Management Appointments Concurrent with Mr. Lundberg’s appointment, Solexa announced the following changes in management responsibility:
“I am delighted we are able to attract an executive of Peter’s caliber as he brings both great technical depth in our field and extensive experience as a manager,” said John West, Solexa’s chief executive officer. “I am committed to building a world-class management team to drive the growth of Solexa and Peter will be a key member. “I would also like to take this opportunity to recognize the accomplishments of Tony Smith and Mary Schramke,” added Mr. West. “Tony provides exceptional leadership, which is evident in his team’s ability to complete our first full-genome sequence announced earlier today. This is a terrific accomplishment and we complement his entire team’s efforts. Mary brings an important combination of scientific and business ability and has been a very effective partner in bringing the recently announced combination of Lynx and Solexa to completion.” - End - About Solexa Solexa is developing DNA sequencing systems for the comprehensive and economical analysis of whole genomes. These systems are intended for use by customers in a wide range of applications from basic research through the development and implementation of personalized medicine. The amount of information required about individual genomes depends upon the scientific application. Present methods generally provide insufficient information and are costly, which has inhibited progress, for instance in understanding the genetic components of common human diseases and the variable response of individuals to drugs. The systems Solexa is developing are designed to provide very large amounts of information about individual genomes including the entire individual human genomic sequence, and to do so economically. Solexa was formed by the recent combination of Solexa Limited with Lynx Therapeutics, Inc. Solexa will continue to provide high volume, short read DNA sequencing services from its Hayward production facility via the Lynx bead-based technology platform until the new fully automated Cluster-SBS instruments begin replacing the older systems later this year and into early 2006. The bead-based systems are mainly used for genome-wide, comprehensive gene expression and small RNA analysis, and the Cluster-SBS technology will enable sequencing services for the broad genome analysis community. Solexa expects to begin testing Cluster-SBS instruments in its production facility by the end of this year and to begin broad commercial sale of instruments in early 2006. This press release contains "forward-looking" statements, including statements related to the current views of Solexa management as to future products, product development, the expansion and success of Solexa’s commercial application of its genomics technologies, and the future financial performance of Solexa. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "predicts," "expects," "envisions," "hopes," "estimates," "intends," "will," "continue," "may," "potential," "should," "confident," "could" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the results of Solexa to differ materially from those indicated by these forward-looking statements including, among others, risks detailed from time to time in the Company’s SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2003, as amended, its Quarterly Report on Form 10-Q for the period ended September 30, 2004 and its Proxy Statement/Prospectus filed pursuant to Rule 424(b)(3) on January 24, 2005. Solexa does not undertake any obligation to update forward-looking statements. For more information, please contact: Solexa, Inc
|
|
|
